Form 4: Compass Therapeutics SVP, CAO Neil Lerner Granted Stock Options

Neil Lerner, SVP and CAO of Compass Therapeutics, was granted stock options for 200,000 shares on February 11, 2025, vesting monthly over four years.

Summary

• Neil Lerner, the SVP and CAO of Compass Therapeutics, was granted stock options on February 11, 2025.
• The options are for 200,000 shares of Compass Therapeutics common stock.
• The exercise price of the options is $3.65 per share.
• The options vest in 48 substantially equal monthly installments, beginning on March 11, 2025.
• The options expire on February 11, 2035.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options is a routine event, but it signals confidence in the executive and aligns their interests with the company's success.

Positives

• The grant of stock options to a key executive like the SVP and CAO can be seen as an incentive to align their interests with the long-term success of the company.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• The size of the grant (200,000 shares) and the vesting schedule (48 months) are typical for an executive at the SVP/CAO level.
• Comparable companies such as BioNTech, Moderna, and Novavax also utilize stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive incentive for the executive to drive company performance.
• Employees may see this as a sign of the company's commitment to its leadership team.

Key Dates